DANIEL ARELLANO: Open Payments
NPI 1346552437 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,878 in 18 payments from 12 companies in 2025. Trend: 2023 $1,501 · 2024 $1,374 · 2025 $1,878
Food & beverage: $1,878
| Company | Payments | Amount |
|---|---|---|
| La Jolla Pharmaceutical Company | 6 | $509 |
| Merck Sharp & Dohme LLC | 2 | $249 |
| ABIOMED | 1 | $138 |
| ABBVIE INC. | 1 | $125 |
| Alcresta Therapeutics, Inc. | 1 | $124 |
| Actelion Pharmaceuticals US, Inc. | 1 | $124 |
| Gilead Sciences, Inc. | 1 | $122 |
| Mallinckrodt Hospital Products Inc. | 1 | $108 |
| Xeris Pharmaceuticals, Inc. | 1 | $107 |
| Melinta Therapeutics, LLC | 1 | $105 |
Products named: GIAPREZA, ZERBAXA, EMBLAVEO, RELIZORB, UPTRAVI, Livdelzi, ZEVTERA, TERLIVAZ.
Industry payments across TX — which companies pay providers there.
